GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (OTCPK:DSRLF) » Definitions » Cyclically Adjusted Revenue per Share

Diasorin SpA (Diasorin SpA) Cyclically Adjusted Revenue per Share : $18.02 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Diasorin SpA's adjusted revenue per share for the three months ended in Dec. 2023 was $6.176. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $18.02 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Diasorin SpA's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 16.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Diasorin SpA was 16.50% per year. The lowest was 6.90% per year. And the median was 13.70% per year.

As of today (2024-04-27), Diasorin SpA's current stock price is $107.40. Diasorin SpA's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $18.02. Diasorin SpA's Cyclically Adjusted PS Ratio of today is 5.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Diasorin SpA was 20.24. The lowest was 4.95. And the median was 9.70.


Diasorin SpA Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Diasorin SpA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Cyclically Adjusted Revenue per Share Chart

Diasorin SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.24 12.90 15.11 17.58 18.02

Diasorin SpA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.58 18.20 17.21 17.51 18.02

Competitive Comparison of Diasorin SpA's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Diasorin SpA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diasorin SpA's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's Cyclically Adjusted PS Ratio falls into.



Diasorin SpA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Diasorin SpA's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=6.176/119.5000*119.5000
=6.176

Current CPI (Dec. 2023) = 119.5000.

Diasorin SpA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2.693 99.907 3.221
201406 2.769 100.093 3.306
201409 2.637 99.814 3.157
201412 2.650 99.721 3.176
201503 2.319 99.814 2.776
201506 2.607 100.279 3.107
201509 2.509 100.000 2.998
201512 2.593 99.814 3.104
201603 2.522 99.600 3.026
201606 2.909 99.900 3.480
201609 3.013 100.100 3.597
201612 3.005 100.300 3.580
201703 3.076 101.000 3.639
201706 3.319 101.100 3.923
201709 3.252 101.200 3.840
201712 3.608 101.200 4.260
201803 3.661 101.800 4.298
201806 3.560 102.400 4.154
201809 3.473 102.600 4.045
201812 3.647 102.300 4.260
201903 3.531 102.800 4.105
201906 3.705 103.100 4.294
201909 3.518 102.900 4.086
201912 3.675 102.800 4.272
202003 3.521 102.900 4.089
202006 4.270 102.900 4.959
202009 4.901 102.300 5.725
202012 6.025 102.600 7.017
202103 5.798 103.700 6.681
202106 5.473 104.200 6.277
202109 7.377 104.900 8.404
202112 7.817 106.600 8.763
202203 7.198 110.400 7.791
202206 6.393 112.500 6.791
202209 6.014 114.200 6.293
202212 6.912 119.000 6.941
202303 5.794 118.800 5.828
202306 5.831 119.700 5.821
202309 5.407 120.300 5.371
202312 6.176 119.500 6.176

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Diasorin SpA  (OTCPK:DSRLF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Diasorin SpA's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=107.40/18.02
=5.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Diasorin SpA was 20.24. The lowest was 4.95. And the median was 9.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Diasorin SpA Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Diasorin SpA (Diasorin SpA) Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin SpA is a biotechnology company engaged in developing, producing, and marketing reagent kits for laboratory diagnostics around the world. The business has focused on the immunodiagnostic market, molecular diagnostics, and Life Science sector. The company has a presence in Italy, Europe, North America, and the Rest of the world, where the majority of its revenue is from North America followed by Italy.